title: Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy.
abstract: Kallikrein 6 (KLK6) is a secreted serine protease preferentially expressed by oligodendroglia in CNS white matter. Elevated levels of KLK6 occur in actively demyelinating multiple sclerosis (MS) lesions and in cases of spinal cord injury (SCI), stroke, and glioblastoma. Taken with recent evidence establishing KLK6 as a CNS-endogenous activator of protease-activated receptors (PARs), we hypothesized that KLK6 activates a subset of PARs to regulate oligodendrocyte physiology and potentially pathophysiology. Here, primary oligodendrocyte cultures derived from wild type or PAR1-deficient mice and the murine oligodendrocyte cell line, Oli-neu, were used to demonstrate that Klk6 (rodent form) mediates loss of oligodendrocyte processes and impedes morphological differentiation of oligodendrocyte progenitor cells (OPCs) in a PAR1-dependent fashion. Comparable gliopathy was also elicited by the canonical PAR1 agonist, thrombin, as well as PAR1-activating peptides (PAR1-APs). Klk6 also exacerbated ATP-mediated oligodendrogliopathy in vitro, pointing to a potential role in augmenting excitotoxicity. In addition, Klk6 suppressed the expression of proteolipid protein (PLP) RNA in cultured oligodendrocytes by a mechanism involving PAR1-mediated Erk1/2 signaling. Microinjection of PAR1 agonists, including Klk6 or PAR1-APs, into the dorsal column white matter of PAR1(+/+) but not PAR1(-/-) mice promoted vacuolating myelopathy and a loss of immunoreactivity for myelin basic protein (MBP) and CC-1(+) oligodendrocytes. These results demonstrate a functional role for Klk6-PAR1 signaling in oligodendroglial pathophysiology and suggest that antagonists of PAR1 or its protease agonists may represent new modalities to moderate demyelination and to promote myelin regeneration in cases of CNS white matter injury or disease.
authors.affiliation: Neurobiology of Disease Program, Mayo Medical and Graduate School, Rochester, Minnesota, USA.
authors.forename: Joshua E
authors.initials: JE
authors.lastname: Burda
authors.forename: Maja
authors.initials: M
authors.lastname: Radulovic
authors.forename: Hyesook
authors.initials: H
authors.lastname: Yoon
authors.forename: Isobel A
authors.initials: IA
authors.lastname: Scarisbrick
mesh_terms: D000255:Adenosine Triphosphate / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000166:cytology; D004195:Disease Models, Animal; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics; D006801:Humans; D007610:Kallikreins / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D004676:Myelin Basic Protein; D018991:Myelin Proteolipid Protein / Q000235:genetics / Q000378:metabolism; D009836:Oligodendroglia / Q000187:drug effects* / Q000378:metabolism*; D044463:Receptor, PAR-1 / Q000819:agonists / Q000172:deficiency / Q000378:metabolism*; D044464:Receptor, PAR-2 / Q000172:deficiency / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D013119:Spinal Cord Injuries / Q000378:metabolism* / Q000473:pathology*; D013917:Thrombin / Q000494:pharmacology
chemical_list: D004676:Myelin Basic Protein; D018991:Myelin Proteolipid Protein; D044463:Receptor, PAR-1; D044464:Receptor, PAR-2; D000255:Adenosine Triphosphate; D007610:Kallikreins; C491223:Prss18 protein, mouse; D013917:Thrombin
keywords: demyelination; myelin; oligodendrocyte; protease-activated receptor; spinal cord; thrombin